Metastasectomy

Metastasectomy: Basics - Goal-Oriented Snipping

• Definition: Surgical excision of metastatic lesions.
• Primary Aim: Improve overall survival (OS); potential cure in oligometastases.
• Other Aims: Symptom palliation, diagnosis, local control.
• Core Principle: Achieve complete R0 resection (microscopically negative margins).
• Crucial Selection Factors:
  • Primary tumor controlled.
  • Patient fit for major surgery (ECOG 0-1).
  • Resectable metastatic disease (number, location).
  • Longer disease-free interval (DFI) often favorable.

⭐ Complete (R0) resection is the most significant prognostic factor for survival after metastasectomy.

Patient Selection Criteria - Picking Prime Patients

• Primary Tumor: Controlled or controllable (no active local disease).
• Metastases:
  • Resectable with clear margins (R0 resection is the goal).
  • Limited number (oligometastases, typically defined as ≤ 3-5 lesions).
  • No widespread, unresectable disease elsewhere.
• Patient Status:
  • Good performance status (e.g., ECOG 0-1, Karnofsky >70).
  • Adequate organ function to tolerate major surgery.
• Timing & Biology:
  • Longer Disease-Free Interval (DFI) from primary treatment (e.g., > 12-24 months preferred).
  • Slow tumor doubling time.

⭐ For pulmonary metastasectomy, a DFI > 36 months, a single metastasis, and complete (R0) resection are strong positive prognostic factors.

Site-Specific Metastasectomy - Hotspot Hitlist

• Liver (Hepatic):
  • Common for CRC. Key: R0 resection, Future Liver Remnant (FLR >20-25% normal, >30-40% chemo-exposed).
  • Parenchymal-sparing preferred.

  ⭐ For CRC liver metastases, 5-year survival post-resection can reach 40-50%.

• Lung (Pulmonary):
  • For CRC, sarcoma, RCC. Key: Primary controlled, R0 resection, pulmonary reserve (FEV1 >1L or >30-40% pred).
  • Wedge resection common, VATS ideal.
• Brain:
  • Solitary/few lesions, controlled primary.
  • Often + Stereotactic Radiosurgery (SRS)/Whole Brain Radiotherapy (WBRT).
  • Primaries: Lung, breast, melanoma.
• Peritoneum (CRS):
  • For peritoneal surface disease (CRC, ovarian, appendiceal).
  • Goal: Complete cytoreduction (CC-0/CC-1). Often + HIPEC.
• Adrenal:
  • Isolated metastasis (e.g., lung, RCC).
  • Laparoscopic adrenalectomy if feasible.

Prognosis & Combined Therapy - Future Factors & Friends

• Prognostic Factors (Influence Outcomes):
  • Favorable (Friends):
    • Long Disease-Free Interval (DFI > 12-24 months).
    • Solitary or few metastases (e.g., < 3-5).
    • Complete (R0) resection achievable.
    • Primary tumor type (e.g., Colorectal CRC, Renal RCC).
    • Good patient performance status (ECOG 0-1).
  • Unfavorable (Foes): Short DFI, multiple/bilateral mets, incomplete resection (R1/R2), aggressive tumor biology.
• Combined Therapy (Synergy for Success):
  • Systemic Therapy: Chemotherapy, immunotherapy, targeted therapy.
    • Neoadjuvant: To downstage, assess tumor biology.
    • Adjuvant: Eradicate micrometastases, improve DFS/OS.
  • Other Local Therapies: SBRT, RFA, MWA for unresectable, residual, or new lesions.
• Future Directions:
  • Liquid biopsies (ctDNA) for early detection & monitoring.
  • Advanced molecular profiling for personalized therapy selection.

⭐ The single most important prognostic factor for survival following metastasectomy is achieving a complete (R0) resection.

High‑Yield Points - ⚡ Biggest Takeaways

• Metastasectomy: surgical resection of metastases, aiming for cure or improved survival.
• Best for oligometastatic disease (limited number/sites of metastases).
• Prognostic factors: disease-free interval (DFI), R0 resection, number/site of metastases.
• Common sites: liver (colorectal cancer), lung (sarcoma, colorectal), brain.
• Crucial selection: good performance status, controlled primary tumor.
• Pulmonary metastasectomy: wedge resection common; R0 resection vital.
• Liver metastasectomy: requires adequate future liver remnant (FLR).